Gubra A/S: Trading statement Q1-2024: Strong start to the year
Gubra releases its results for the first quarter of 2024. For the CRO business, performance was strong with organic revenue growth of 51% year-over-year. Within the D&P business, there was significant ...
Gubra A/S: Gubra raises financial outlook for 2024
Gubra announces an upgrade to its full-year 2024 financial outlook. Organic revenue growth for the CRO business is now expected to be 15-20% (previously 10-15%) and adjusted EBIT-margin is expected ...
ahajournals.org9d
Arteriosclerosis Obliterans: Review of 520 Cases with Special Reference to Pathogenic and Prognostic Factors
From the Mayo Clinic and the Mayo Foundation, Rochester, Minn. The Mayo Foundation, Rochester, Minn., is a part of the Graduate School of the University of Minnesota. From the Mayo Clinic and the Mayo ...
ahajournals.org3d
Arrhythmogenic Right Ventricular Cardiomyopathy and Fatty Replacement of the Right Ventricular Myocardium
From the Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, Washington, DC. Conclusions—ARVC is a familial arrhythmogenic disease characterized by fibrofatty replacement of ...